Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 17/20 | 0.63 |
| ▸ | CHRNA3 | P32297 | 17/20 | 0.63 |
| ▸ | CHRNA4 | P43681 | 17/20 | 0.63 |
| ▸ | CHRNB3 | Q05901 | 17/20 | 0.63 |
| ▸ | CHRNA6 | Q15825 | 17/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17190676 | 0.82 | SMN1; SMN2 (0.53) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL13401071 | 0.81 | SMN1; SMN2 (0.53) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL12197935 | 0.81 | SMN1; SMN2 (0.53) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL25504806 | 0.80 | SMN1; SMN2 (0.52) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL1711353 | 0.80 | CHRNB2 (0.54) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL15131744 | 0.78 | SMN1; SMN2 (0.55) | SMN1; SMN2POLBNPSR1L3MBTL1 | |
| SCHEMBL24974012 | 0.78 | SMN1; SMN2 (0.59) | CHRNB2CHRNA4SMN1; SMN2POLBNPSR1 | |
| SCHEMBL1978271 | 0.78 | CHRNB2 (1.00) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL19104799 | 0.78 | SMN1; SMN2 (0.53) | SMN1; SMN2POLBNPSR1L3MBTL1 | |
| SCHEMBL15490020 | 0.78 | SMN1; SMN2 (0.53) | SMN1; SMN2POLBNPSR1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140315880-A1 | 3,6-DIAZABICYCLO[3.1.1]HEPTAINES AS NEURONAL NICOTINIC ACETYCHOLINE RECEPTOR LIGANDS | TARGACEPT INC (US) | 2014-10-23 | — | — | US | disclosed |
| US-20140315880-A1 | 3,6-DIAZABICYCLO[3.1.1]HEPTAINES AS NEURONAL NICOTINIC ACETYCHOLINE RECEPTOR LIGANDS | TARGACEPT INC (US) | 2014-10-23 | — | — | US | disclosed |
| US-8802694-B2 | 3,6-diazabicyclo[3.1.1]heptanes as neuronal nicotinic acetycholine receptor ligands | TARGACEPT, INC. (US) | 2014-08-12 | — | — | US | disclosed |
| US-8802694-B2 | 3,6-diazabicyclo[3.1.1]heptanes as neuronal nicotinic acetycholine receptor ligands | TARGACEPT, INC. (US) | 2014-08-12 | — | — | US | disclosed |
| US-20120309737-A1 | 3,6-Diazabicyclo[3.1.1]heptanes as Neuronal Nicotinic Acetycholine Receptor Ligands | TARGACEPT, INC. (US) | 2012-12-06 | — | — | US | disclosed |
| US-20120309737-A1 | 3,6-Diazabicyclo[3.1.1]heptanes as Neuronal Nicotinic Acetycholine Receptor Ligands | TARGACEPT, INC. (US) | 2012-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140315880-A1 | 3,6-DIAZABICYCLO[3.1.1]HEPTAINES AS NEURONAL NICOTINIC ACETYCHOLINE RECEPTOR LIGANDS | CHRNA7, CHRNA3, CHRNA6 | CHRNB2 9/4885CHRNA3 2/4885CHRNA4 6/4885 |
| US-20120309737-A1 | 3,6-Diazabicyclo[3.1.1]heptanes as Neuronal Nicotinic Acetycholine Receptor Ligands | CHRNA3, CHRNA2, CHRNA6 | CHRNB2 9/4885CHRNA3 1/4885CHRNA4 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.